Biocon Ltd (BOM:532523) Q3 2025 Earnings Call Highlights: Strong ...

Feb 1, 2025 · For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points. Biocon Ltd reported a 10% year-on-year growth in operating …

CouponFollow Extension

10%
OFF

Biocon Ltd (BOM:532523) Q3 2025 Earnings Call Highlights: Strong ...

2 weeks from now

Feb 1, 2025 · For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points. Biocon Ltd reported a 10% year-on-year growth in operating …

yahoo.com

14%
OFF

Biocon Ltd (BOM:532523) Q3 2025 Earnings Call Highlights: Strong ...

2 weeks from now

Biocon Ltd (BOM:532523) achieved key product approvals in both biologics and generics, with new product launches planned for Q4. The biosimilars segment showed a 14% year-on-year …

investing.com

7%
OFF

Biocon Q3FY25 Revenue At Rs 3,856 Cr, Up 7%# EBITDA At Rs 787 …

2 weeks from now

Jan 30, 2025 · Financial Commentary: Q3FY25. Consolidated Total Revenue for Q3FY25 was at Rs 3,856 crore.Reported 7% YoY growth on a like-for-like basis, after adjusting for Branded …

biocon.com

4%
OFF

Biocon Ltd (BOM:532523) (H1 2025) Earnings Call Highlights: …

2 weeks from now

For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points. Biocon Ltd reported operating revenue growth of 4%, with an 8% increase on a ...

yahoo.com

4%
OFF

Biocon Ltd's Q3FY25 Quarter Results - Kotaksecurities.com

2 weeks from now

Jan 31, 2025 · In the third quarter of fiscal year 2025, Biocon Ltd reported a total income of ₹3856.20 crores, which represents a 6.4% increase quarter-over-quarter from ₹3622.90 crores …

kotaksecurities.com

FAQs about Biocon Ltd (BOM:532523) Q3 2025 Earnings Call Highlights: Strong ... Coupon?

Why did Biocon grow 10 per cent sequential revenue?

Siddharth Mittal, chief executive officer and managing director, Biocon, noted, “The 10 per cent sequential revenue growth in the generics business was primarily driven by API sales, supported by an improved performance from generic formulations. We expect to see an improved performance in the quarters ahead.” ...

How did Biocon biologics perform in the US biotech market?

The contract development and manufacturing organisation (CDMO), driven by biologics, saw positive momentum, indicating stabilising US biotech market dynamics, though later than expected. Biocon Biologics reported revenue from operations of Rs 2,289 crore, reflecting a 14 per cent yearly increase on a like-for-like basis. ...

How did Biocon biologics perform compared to Syngene?

Biocon Biologics continues to expand its global footprint, achieving double-digit growth in the UK and Mediterranean regions. Overall performance was relatively muted due to continued pressures in the generic business and a marginal decline in Syngene's revenues. ...